The battle between pharma companies and hospitals over the federal drug discount program known as 340B is gaining steam as its size has tripled since 2018 and may even double again, according to a new IQVIA report.
The 340B program, which essentially cuts the prices of certain outpatient drugs by 55% for hospitals and clinics, saw 16.5% growth in 2023, up from 12% in 2022, the report said. By comparison, pharma sales outside of the 340B program grew more slowly, IQVIA notes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.